Development and Applications of Initial Dosage Setting of Cibenzoline in Consideration of the Cases of Adverse Reaction Induced by Cibenzoline on Clinical Services in a Hospital.

Y. Maeda, T. Konishi, K. Omoda, Y. Takeda, H. Fujii, I. Kanazawa, S. Eno, S. Tsukiai
{"title":"Development and Applications of Initial Dosage Setting of Cibenzoline in Consideration of the Cases of Adverse Reaction Induced by Cibenzoline on Clinical Services in a Hospital.","authors":"Y. Maeda, T. Konishi, K. Omoda, Y. Takeda, H. Fujii, I. Kanazawa, S. Eno, S. Tsukiai","doi":"10.5649/JJPHCS1975.26.239","DOIUrl":null,"url":null,"abstract":"Adverse reactions induced by cibenzoline at this hospital showed the trough value of cibenzoline at the time to be above 400ng/mL. In these cases, by adjusting the trough values to 150-230ng/mL and also by reducing the cibenzoline dosage, the effects of cibenzoline could thus be maintained while adverse reactions were avoided. Therefore, the relationship between the trough value based on cibenzoline dosage and the creatinine clearance in 19 cases who took cibenzoline was examined. In order to adjust trough level to 150-250ng/mL as the goal concentration based on the relation formula, the recommended dosage of cibenzoline and the creatinine clearance were calculated. The utility of an initial dosage setting according to the combination a recommended dosage of cibenzoline and the creatinine clearance nomogram reported by Nielsen et al. was examined in 9 cases.As a result, using this nomogram, the percentage of the goal concentration thus significantly increased, while the percentage of hypoglycemia significantly decreased. Accordingly, the nomogram of cibenzoline prepared in our hospital was thus concluded to be clinically acceptable.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"38 1","pages":"239-249"},"PeriodicalIF":0.0000,"publicationDate":"2000-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5649/JJPHCS1975.26.239","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Adverse reactions induced by cibenzoline at this hospital showed the trough value of cibenzoline at the time to be above 400ng/mL. In these cases, by adjusting the trough values to 150-230ng/mL and also by reducing the cibenzoline dosage, the effects of cibenzoline could thus be maintained while adverse reactions were avoided. Therefore, the relationship between the trough value based on cibenzoline dosage and the creatinine clearance in 19 cases who took cibenzoline was examined. In order to adjust trough level to 150-250ng/mL as the goal concentration based on the relation formula, the recommended dosage of cibenzoline and the creatinine clearance were calculated. The utility of an initial dosage setting according to the combination a recommended dosage of cibenzoline and the creatinine clearance nomogram reported by Nielsen et al. was examined in 9 cases.As a result, using this nomogram, the percentage of the goal concentration thus significantly increased, while the percentage of hypoglycemia significantly decreased. Accordingly, the nomogram of cibenzoline prepared in our hospital was thus concluded to be clinically acceptable.
考虑到苯并啉在临床服务中引起的不良反应,苯并啉初始剂量设定的制定与应用。
该院苯并啉引起的不良反应,当时苯并啉的波谷值在400ng/mL以上。通过调整波谷值为150 ~ 230ng/mL,同时减少苯并啉的用量,可以维持苯并啉的治疗效果,同时避免不良反应的发生。因此,我们对19例服用苯并啉的患者进行了基于苯并啉用量的波谷值与肌酐清除率的关系研究。根据关系式,将药谷水平调整为150 ~ 250ng/mL为目标浓度,计算苯并啉推荐用量与肌酐清除率。根据尼尔森等人报道的推荐剂量和肌酸酐清除率图的组合,对9例患者进行了初始剂量设置的效用检验。因此,使用此图,目标浓度的百分比因此显著增加,而低血糖的百分比显着降低。由此得出我院所制备的苯并啉的形态图在临床上是可以接受的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信